Loncastuximab Tesirine-Lpyl Application Scope

Loncastuximab tesirine-lpyl (brand name: Zynlonta) is an antibody-drug conjugate (ADC) used in the treatment of relapsed or refractory B-cell lymphoma, particularly in cases where prior treatments have failed.

Loncastuximab tesirine-lpyl is primarily indicated for

Relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL).
Used in patients who have previously received at least two prior therapies.

Loncastuximab Package Insert

Ingredients: Loncastuximab tesirine-lpy consists of an anti-CD19 monoclonal antibody (loncastuximab) conjugated to a cytotoxic drug (tesirine), which is a pyrrolobenzodiazepine (PBD) dimer.
Properties: It is an antibody-drug conjugate designed to target CD19, a protein found on the surface of B-cells, and deliver cytotoxic therapy directly to the tumor.
Specification: Available as a single-use vial for intravenous infusion.
Packaging Specification: Single-use vials, typically 100 mg/5 mL (20 mg/mL).
Storage: Store in the original carton at 2°C to 8°C (36°F to 46°F). Do not freeze.
Expiry Date: Refer to the vial for expiry.
Executive Standard: Compliance with relevant regulatory standards (FDA approved).
Approval Number: Available in the drug label.
Date of Revision: As per the latest official label.
Manufacturer: ADC Therapeutics SA.

Guidelines For The Use of Loncastuximab Tesirine-Lpyl

Dosage and Administration:

Initial dose: 0.15 mg/kg body weight administered intravenously every 3 weeks.
Administration method: Administer via intravenous infusion over 30 minutes.
Monitoring: Monitor patients for infusion-related reactions and manage accordingly.

Adverse Reactions:

Loncastuximab side effects: Fatigue, nausea, thrombocytopenia, neutropenia, anemia.
Severe: Cytokine release syndrome, infusion-related reactions, hepatotoxicity, infections.

Loncastuximab Tesirine-Lpyl Medication Limitations

Contraindications:

Hypersensitivity to loncastuximab tesirine or any component of the formulation.
Active infections or severe cytopenias (low blood cell counts).

Precautions:

Patients with liver dysfunction may need dose adjustments.
Monitor for signs of infusion-related reactions and cytokine release syndrome.
Regular blood count monitoring is recommended, especially during the first few cycles.

Loncastuximab Tesirine-Lpyl Interactions

Drug Interactions:

Immunosuppressive agents: Concomitant use with other immunosuppressive therapies may increase the risk of infections.
Vaccines: Live vaccines should be avoided during therapy.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.